Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · IEX Real-Time Price · USD
4.430
-0.070 (-1.56%)
Jul 22, 2024, 10:13 AM EDT - Market open
Scinai Immunotherapeutics Employees
Scinai Immunotherapeutics had 31 employees as of December 31, 2023. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
n/a
Profits / Employee
-$635,419
Market Cap
3.68M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Venus Concept | 304 |
Regional Health Properties | 114 |
Xylo Technologies | 84 |
Fresh2 Group | 75 |
Avinger | 72 |
Applied DNA Sciences | 55 |
Aptevo Therapeutics | 40 |
Bio-Path Holdings | 10 |
SCNI News
- 6 days ago - Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results - Invezz
- 7 days ago - Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model - PRNewsWire
- 14 days ago - Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity - PRNewsWire
- 19 days ago - Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - PRNewsWire
- 20 days ago - Scinai Publishes Q1 2024 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity. - PRNewsWire
- 6 weeks ago - Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement - PRNewsWire
- 2 months ago - Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance - PRNewsWire